Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non–Small Cell Lung Cancer
- Conditions
- Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor AberrationsMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2022-000578-25-DE
- Lead Sponsor
- Gilead Sciences, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 780
Members of all genders, races, and ethnic groups are eligible for this study.
Participants must meet all of the following inclusion criteria to be eligible for participation in this study (no waivers for participant eligibility will be permitted).
1)Participants assigned male at birth and participants assigned female at birth, 18 years of age or older, able to understand and give written informed consent.
2)Life expectancy = 3 months.
3)Pathologically documented NSCLC that meets both of the criteria below:
a)Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on AJCC, Eighth Edition).
b)Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations.
Note:Tumor testing for EGFR or ALK mutations is required if status is unknown
4)Have no known genomic alterations in ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other actionable driver oncogenes with approved therapies (actionable genomic alteration). Testing is not required if status is unknown.
5)Provide adequate tumor tissue from locations not radiated prior to biopsy to evaluate PD-L1 status prior to randomization.
6)Have not received prior systemic treatment for metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of study treatment.
7)Measurable disease by CT or MRI as per RECIST v1.1 criteria by investigator assessment.
8)ECOG PS score of 0 or 1.
9)Organ function requirement.
10)Participants assigned male at birth and participants assigned female at birth of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
11)Willing and able to comply with the requirements and restrictions in this protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 600
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 120
Participants who meet any of the following exclusion criteria at screening/Day -1 are not eligible to be enrolled in this study (no waivers for participant eligibility will be offered or permitted):
1)Have mixed small-cell lung cancer (SCLC) and NSCLC histology.
2)Positive serum pregnancy test or participants who are breastfeeding or have plans to breastfeed during the study period and for the required duration of contraception use after the last dose of study drug.
3)Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint. Participants who received PD-(L)1 inhibitors as a part of treatment for early stage NSCLC including in neoadjuvant/adjuvant setting are not eligible.
4)Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
5)Requirement for ongoing therapy with or prior use of any prohibited medications listed in Section 5.6.3.
6)Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment. Participants with a history of malignancy that has been completely treated, with no evidence of active cancer for at least 3 years prior to enrollment, or with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.
7)Have an active autoimmune disease that required systemic treatment in past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
8)Are receiving chronic systemic steroids. Use of topical, inhalational, intra-nasal, and intra-ocular steroids will be permitted.
9)Have significant third-space fluid retention (eg, ascites or pleural effusion) and is not amenable for required repeated drainage
10)Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to enrollment and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases and are not requiring use of steroids for at least 14 days prior to the start of study treatment. All participants with carcinomatous meningitis are excluded regardless of clinical stability.
11)Meet any of the following criteria for cardiac disease:
a)Myocardial infarction or unstable angina pectoris within 6 months of enrollment.
b)History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
c)NYHA Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%.
12)Active chronic inflammatory bowel disease (ulcerative colitis, Crohn’s disease) or gastrointestinal perforation within 6 months of enrollment.
13)Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
14)Has received radiotherapy within 2 weeks prior to first dose of study intervention or radiother
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method